MAbs with TK inhibitors targeting EGFR, a tyrosine kinase (TK), which is a receptor for therapeutic agents for glioblastoma such as T cells, oncolytic viruses, and nanoparticles is being investigated (39). Here, EGFR is linked to glioblastoma.